Eftilagimod alpha - Immutep Limited

Drug Profile

Eftilagimod alpha - Immutep Limited

Alternative Names: EDP-202; Efti; EOC202; hLAG-3Ig; ImmuFact IMP321; IMP321; LAG-3-Ig-fusion-protein; LAG-3Ig; sLAG-3-Ig

Latest Information Update: 14 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immutep
  • Developer Immutep; Immutep Limited; Krankenhaus Nordwest; Prima BioMed
  • Class Adjuvants; Antineoplastics; CD antigens; Immunoglobulins; Recombinant fusion proteins
  • Mechanism of Action Antigen presenting cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Malignant melanoma; Solid tumours
  • No development reported Renal cell carcinoma

Most Recent Events

  • 08 Aug 2018 EOC Pharma plans clinical trial for eftlagimod in combination with paclitaxel in Metastatic breast cancer in third quarter of 2018 in China
  • 07 Aug 2018 Immutep Limited completes enrolment in the phase I TACTI-mel trial for Malignant melanoma (Adjunctive treatment, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Australia
  • 31 Jul 2018 Updated efficacy data from phase I TACTI-Mel trial in Malignant melanoma released by Immuntep
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top